TP53 and cancer: Mutant lines of medaka have been developed that affect BLM, which is associated with progeria in humans, PARK2, which is associated with hereditary Parkinson's disease, SIRT1, which is the homolog of a gene that affects aging in budding yeast, and TP53, which is associated with Li-Fraumeni syndrome and frequently undergoes somatic mutation in cancer [43].